iShares Biotechnology ETF (NASDAQ:IBB) Shares Bought by Rye Brook Capital LLC

Rye Brook Capital LLC grew its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 0.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,500 shares of the financial services provider’s stock after acquiring an additional 200 shares during the period. iShares Biotechnology ETF comprises about 3.4% of Rye Brook Capital LLC’s holdings, making the stock its 11th biggest position. Rye Brook Capital LLC’s holdings in iShares Biotechnology ETF were worth $2,750,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of IBB. Guardian Wealth Advisors LLC NC raised its position in shares of iShares Biotechnology ETF by 24.8% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 372 shares of the financial services provider’s stock worth $49,000 after purchasing an additional 74 shares during the last quarter. Ally Invest Advisors Inc. raised its position in shares of iShares Biotechnology ETF by 5.3% during the 4th quarter. Ally Invest Advisors Inc. now owns 1,515 shares of the financial services provider’s stock worth $200,000 after purchasing an additional 76 shares during the last quarter. Arete Wealth Advisors LLC raised its position in shares of iShares Biotechnology ETF by 4.2% during the 4th quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock worth $263,000 after purchasing an additional 80 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in iShares Biotechnology ETF by 3.0% in the 4th quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock valued at $363,000 after acquiring an additional 81 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after acquiring an additional 82 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $128.00 on Friday. The stock has a fifty day moving average of $121.95 and a two-hundred day moving average of $130.48. The company has a market capitalization of $5.60 billion, a PE ratio of 23.96 and a beta of 0.84. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Increases Dividend

The firm also recently declared a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were issued a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.